Stocks · Healthcare · Biotechnology
Fate Therapeutics, Inc. FATE
$2.32 +0.87% Close, Oct 2, 2026 · NASDAQ · Market cap $270.4M
Strong trendExpensive vs sectorHigh risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to -2058.1% from -2271.2% a year earlier.
- Over the past year the stock returned +85.6%, ahead of the S&P 500 by 70.5 percentage points.
- The stock is in an uptrend: above its 200-day average for 124 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 15%
- Revenue growth, 3-year CAGRBottom 2%
- Revenue growth accelerationTop 7%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 21%
- Gross marginBottom 4%
- Operating marginBottom 9%
- Accruals (lower is better)Top 37%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 16%
- Free-cash-flow yieldBottom 12%
- EBITDA / enterprise valueBottom 18%
- Sales / enterprise valueBottom 13%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 18%
- 6-month returnTop 10%
- 1-year return vs S&P 500Top 17%
- Distance from 52-week highTop 44%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 48%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 18%
- Upside to consensus price targetTop 27%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 44%
- Maximum drawdown, 3 yearsBottom 11%
- Beta vs S&P 500 (lower is better)Bottom 3%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -52.6% | -23.4% | ↑ |
| Gross margin | -900.5% | -343.0% | ↑ |
| Operating margin | -2271.2% | -2058.1% | ↑ |
| FCF margin | -1402.2% | -1627.8% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -23.4% | -52.6% | ↑ | Bottom 15% |
| Gross margin | -343.0% | -900.5% | ↑ | Bottom 4% |
| Operating margin | -2058.1% | -2271.2% | ↑ | Bottom 9% |
| Net margin | -1941.1% | -2025.1% | ↑ | — |
| Free-cash-flow margin | -1627.8% | -1402.2% | ↓ | — |
| Return on invested capital | -57.5% | — | Bottom 21% | |
| Revenue growth, 3-year CAGR | -59.0% | — | Bottom 2% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -9.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 274.8%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -26.2 pp
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.15%
- Shareholder yield
- -0.15%
- Share count change, 1 year
- +1.6%
- Share count change, 3-year CAGR
- +7.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +4.7%
- Average 2-day reaction, last 8
- -3.8%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $5.63
- Target vs current price
- +142.7%
- Analysts with a rating
- 31
- Share rating Buy or Strong Buy
- 52%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 13, 2026 | +1.4% | -7.4% | -2.6% | -14.3% | — |
| May 13, 2026 | +10.3% | -5.3% | -16.0% | -16.9% | +24.4% |
| Feb 26, 2026 | +0.0% | +5.4% | -2.0% | -17.6% | +41.9% |
| Nov 13, 2025 | +6.9% | -4.6% | +1.0% | +6.7% | +4.8% |
| Aug 12, 2025 | +17.1% | +0.1% | +28.2% | +4.7% | +27.2% |
| May 13, 2025 | +17.9% | -6.5% | +14.0% | +56.1% | -8.4% |
| Mar 5, 2025 | +0.0% | -4.7% | +1.0% | -20.3% | +38.9% |
| Nov 12, 2024 | +4.8% | -7.0% | -11.3% | -10.9% | -51.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.25 | -$0.25 | +1.4% | $2.1M |
| May 13, 2026 | -$0.26 | -$0.29 | +10.3% | $1.3M |
| Feb 26, 2026 | -$0.27 | -$0.27 | +0.0% | $1.4M |
| Nov 13, 2025 | -$0.27 | -$0.29 | +6.9% | $1.7M |
| Aug 12, 2025 | -$0.29 | -$0.35 | +17.1% | $1.9M |
| May 13, 2025 | -$0.32 | -$0.39 | +17.9% | $1.6M |
| Mar 5, 2025 | -$0.44 | -$0.44 | +0.0% | $1.9M |
| Nov 12, 2024 | -$0.40 | -$0.42 | +4.8% | $3.1M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 48.32× | — | — | Bottom 13% |
| Free-cash-flow yield | -39.07% | — | — | Bottom 12% |
| Earnings yield | -45.26% | — | — | Bottom 16% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 124
- 50-day average slope (20 days)
- -5.5%
- 200-day average slope (20 days)
- +7.8%
- Distance from 50-day average
- -6.3%
- Distance from 200-day average
- +25.3%
- RSI (14)
- 42.2
- Relative volume
- 0.43×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 58.6%
- Volatility vs own 5-year history
- 3th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.75
- Correlation with S&P 500
- 0.38
- Current drawdown from 1-year high
- -25.4%
- Maximum drawdown, 3 years
- -91.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 14, 2021 | Apr 3, 2025 | -99.4% | 1059 days | Not yet recovered |
| Dec 22, 2020 | Jan 5, 2021 | -14.1% | 8 days | 2 days (Jan 7, 2021) |
| Oct 13, 2020 | Nov 2, 2020 | -10.4% | 14 days | 2 days (Nov 4, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $270.4M
- EPS, diluted (TTM)
- -$1.05
- Revenue (TTM)
- $6.5M
- 52-week range
- $0.95 – $3.23
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Gross profit | $50.0M | $82.5M | -$93.7M | -$104.9M | -$6.3M |
| Operating income | -$217.0M | -$308.4M | -$190.5M | -$210.3M | -$147.7M |
| Net income | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| EPS (diluted) | -$2.24 | -$2.91 | -$1.64 | -$1.64 | -$1.15 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $1.9M | $1.6M | $1.9M | $1.7M | $1.4M | $1.3M | $2.1M |
| Net income | -$47.7M | -$52.2M | -$37.6M | -$34.1M | -$32.3M | -$32.4M | -$31.2M | -$30.2M |
| EPS (diluted) | -$0.40 | -$0.44 | -$0.32 | -$0.29 | -$0.27 | -$0.27 | -$0.26 | -$0.25 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$162.9M | -$248.2M | -$132.3M | -$122.9M | -$106.1M |
| Capital expenditure | -$50.7M | -$35.6M | -$6.2M | -$730,000 | -$6.0M |
| Free cash flow | -$213.6M | -$283.8M | -$138.4M | -$123.6M | -$112.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $411.7M | $9.2M | $85,000 | $94.8M | $0 |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $153.8M
- Total assets
- $260.1M
- Total liabilities
- $106.7M
- Total debt
- $75.7M
- Net debt
- $43.2M
- Shareholders’ equity
- $153.4M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 9,386,451
- Days to cover
- 10.50
- Change vs previous report
- +3.0%
FINRA short interest, settlement date Sep 15, 2026.